Kymera Therapeutics, Inc. (KYMR) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Watertown, MA, United States. Der aktuelle CEO ist Nello Mainolfi.
KYMR hat IPO-Datum 2020-08-21, 208 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $7.34B.
Kymera Therapeutics, Inc. is a biopharmaceutical company founded in 2015 and based in Watertown, Massachusetts that specializes in discovering and developing small molecule therapeutics designed to selectively degrade disease-causing proteins using the body's natural protein degradation system. The company's pipeline includes the IRAK4 program currently in Phase I clinical trials for immunology and inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; the IRAKIMiD program targeting MYD88-mutated diffuse large B cell lymphoma; the STAT3 program for treating hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis; and the MDM2 program for hematological and solid tumors. Through its proprietary protein degradation platform, Kymera aims to address significant unmet medical needs across oncology, immunology, and other therapeutic areas.
